Atripla R/anti-TB combination in TB/HIV patients. Drug in focus

2Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND:Co-administration of anti-tuberculosis and antiretroviral therapy is often inevitable in high-burden countries where tuberculosis is the most common opportunistic infection associated with HIV/AIDS. Concurrent use of rifampicin and several antiretroviral drugs is complicated by pharmacokinetic drug-drug interaction.METHOD:Pubmed and Google search following the key words tuberculosis, HIV, emtricitabine, tenofovir efavirenz, interaction were used to find relevant information on each drug of the fixed dose combination AtriplaRRESULTS:Information on generic name, trade name, pharmacokinetic parameter, metabolism and the pharmacokinetic interaction with Anti-TB drugs of emtricitabine, tenofovir, and efavirenz was obtained.CONCLUSION:Fixed dose combination of emtricitabine/tenofovir/efavirenz (ATRIPLAR) which has been approved by Food and Drug Administration shows promising results as far as safety and efficacy is concerned in TB/HIV co-infection patients, hence can be considered effective and safe antiretroviral drug in TB/HIV management for adult and children above 3 years of age.

Cite

CITATION STYLE

APA

Semvua, H. H., & Kibiki, G. S. (2011). Atripla R/anti-TB combination in TB/HIV patients. Drug in focus. BMC Research Notes, 4. https://doi.org/10.1186/1756-0500-4-511

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free